Compare KGS & TMDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | KGS | TMDX |
|---|---|---|
| Founded | 2011 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.5B | 2.2B |
| IPO Year | 2023 | 2019 |
| Metric | KGS | TMDX |
|---|---|---|
| Price | $73.41 | $68.76 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 7 | 9 |
| Target Price | $57.17 | ★ $148.22 |
| AVG Volume (30 Days) | ★ 1.8M | 1.7M |
| Earning Date | 05-06-2026 | 05-05-2026 |
| Dividend Yield | ★ 2.93% | N/A |
| EPS Growth | 58.93 | ★ 382.18 |
| EPS | 0.20 | 0.20 |
| Revenue | ★ $1,308,100,000.00 | $605,494,000.00 |
| Revenue This Year | $12.30 | $24.25 |
| Revenue Next Year | $7.96 | $18.75 |
| P/E Ratio | $362.25 | ★ $343.30 |
| Revenue Growth | 12.83 | ★ 37.13 |
| 52 Week Low | $30.06 | $60.11 |
| 52 Week High | $77.68 | $156.00 |
| Indicator | KGS | TMDX |
|---|---|---|
| Relative Strength Index (RSI) | 61.09 | 31.56 |
| Support Level | $33.80 | $60.11 |
| Resistance Level | $76.68 | $142.44 |
| Average True Range (ATR) | 2.91 | 4.65 |
| MACD | -0.37 | 0.48 |
| Stochastic Oscillator | 54.61 | 22.22 |
Kodiak Gas Services Inc is an operator of contract compression infrastructure in the United States. It manages business through two operating segments namely Contract Services and Other Services. Contract Services consists of operating Company-owned and customer-owned compression, and gas treating and cooling infrastructure, pursuant to fixed-revenue contracts to enable the production and gathering of natural gas and oil. Other Services consist of a full range of contract services to support the ancillary needs of customers, including station construction, maintenance and overhaul, freight and crane charges, and other time and material-based offerings.
TransMedics Group Inc is a commercial-stage medical technology company transforming organ transplant therapy for end-stage organ failure patients across multiple disease states. It has developed the Organ Care System (OCS) to comprehensively address the limitations of cold storage. The OCS is a portable organ perfusion, optimization, and monitoring system that utilizes technology to replicate near-physiologic conditions for donor organs outside of the human body. The company has developed and is commercializing a proprietary system to preserve and deliver human organs for transplant in a near-physiologic condition to address the limitations of cold storage organ preservation.